NASDAQ:SRRA - Sierra Oncology Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $37.00
  • Forecasted Upside: 76.02 %
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$21.02
▲ +0.23 (1.11%)

This chart shows the closing price for SRRA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sierra Oncology Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SRRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SRRA

Analyst Price Target is $37.00
▲ +76.02% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Sierra Oncology in the last 3 months. The average price target is $37.00, with a high forecast of $39.00 and a low forecast of $35.00. The average price target represents a 76.02% upside from the last price of $21.02.

This chart shows the closing price for SRRA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 2 polled investment analysts is to buy stock in Sierra Oncology. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/25/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/23/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/22/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/20/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/19/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
12/17/2021HC WainwrightReiterated RatingBuy$35.00Low
12/10/2021HC WainwrightReiterated RatingBuy$35.00High
11/30/2021Cantor FitzgeraldBoost Price TargetOverweight$33.00 ➝ $39.00Low
11/5/2021HC WainwrightBoost Price TargetBuy$29.00 ➝ $35.00Medium
9/27/2021Cantor FitzgeraldInitiated CoverageOverweight$33.00Low
6/21/2021HC WainwrightReiterated RatingBuy$29.00High
6/14/2021HC WainwrightReiterated RatingBuy$29.00High
12/11/2020HC WainwrightReiterated RatingBuy$29.00High
11/10/2020OppenheimerReiterated RatingBuy$27.00Low
11/6/2020Lifesci CapitalReiterated RatingOutperformLow
7/30/2020HC WainwrightInitiated CoverageBuy$20.00Low
6/14/2020OppenheimerReiterated RatingBuy$48.00Low
5/13/2020OppenheimerReiterated RatingBuyHigh
12/5/2019OppenheimerInitiated CoverageOutperform$1.20High
2/28/2019WedbushReiterated RatingOutperformMedium
10/23/2017Jefferies Financial GroupUpgradeHold ➝ BuyN/A
7/27/2017Jefferies Financial GroupReiterated RatingHoldMedium
3/10/2017SunTrust BanksUpgradeHold ➝ Buy$4.00High
3/6/2017WedbushReiterated RatingOutperform$4.00N/A
2/22/2017WedbushUpgradeNeutral ➝ Outperform$3.00 ➝ $4.00N/A
(Data available from 1/18/2017 forward)

News Sentiment Rating

0.84 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/22/2021
  • 2 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/22/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
8/21/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/20/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
10/20/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 3 negative mentions
  • 1 very negative mentions
11/19/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
12/19/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
1/18/2022

Current Sentiment

  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.
Sierra Oncology logo
Sierra Oncology, Inc. is a clinical stage drug development company of therapeutics for the treatment of cancer. The firm focuses on advancing targeted therapeutics for the treatment of patients with significant unmet medical needs in hematology and oncology. Its product Momelotinib, a selective and orally-bioavailable JAK1, JAK2 & ACVR1 inhibitor with a differentiated therapeutic profile in myelofibrosis encompassing robust constitutional symptom improvements. The company was founded on May 8, 2003 and is headquartered in Vancouver, Canada.
Read More

Today's Range

Now: $21.02
Low: $20.02
High: $21.74

50 Day Range

MA: $22.34
Low: $20.79
High: $23.50

52 Week Range

Now: $21.02
Low: $13.68
High: $24.00

Volume

41,961 shs

Average Volume

78,980 shs

Market Capitalization

$316.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.8

Frequently Asked Questions

What sell-side analysts currently cover shares of Sierra Oncology?

The following equities research analysts have issued stock ratings on Sierra Oncology in the last year: Cantor Fitzgerald, HC Wainwright, and Zacks Investment Research.
View the latest analyst ratings for SRRA.

What is the current price target for Sierra Oncology?

2 Wall Street analysts have set twelve-month price targets for Sierra Oncology in the last year. Their average twelve-month price target is $37.00, suggesting a possible upside of 76.0%. Cantor Fitzgerald has the highest price target set, predicting SRRA will reach $39.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $35.00 for Sierra Oncology in the next year.
View the latest price targets for SRRA.

What is the current consensus analyst rating for Sierra Oncology?

Sierra Oncology currently has 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe SRRA will outperform the market and that investors should add to their positions of Sierra Oncology.
View the latest ratings for SRRA.

How do I contact Sierra Oncology's investor relations team?

Sierra Oncology's physical mailing address is 2150-885 WEST GEORGIA STREET, VANCOUVER A1, V6C 3E8. The biotechnology company's listed phone number is (604) 558-6536 and its investor relations email address is [email protected] The official website for Sierra Oncology is www.sierraoncology.com.